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BACKGROUND: The index of microcirculatory resistance (IMR) of the infarct-related artery and left ventricular end-diastolic 
pressure (LVEDP) are acute, prognostic biomarkers in patients undergoing primary percutaneous coronary intervention. The 
clinical significance of IMR and LVEDP in combination is unknown.
METHODS: IMR and LVEDP were prospectively measured in a prespecified substudy of the T-TIME clinical trial (Trial of Low 
Dose Adjunctive Alteplase During Primary PCI). IMR was measured using a pressure- and temperature-sensing guidewire 
following percutaneous coronary intervention. Prognostically established thresholds for IMR (>32) and LVEDP (>18 mm Hg) 
were predefined. Contrast-enhanced cardiovascular magnetic resonance imaging (1.5 Tesla) was acquired 2 to 7 days and 
3 months postmyocardial infarction. The primary end point was major adverse cardiac events, defined as cardiac death/
nonfatal myocardial infarction/heart failure hospitalization at 1 year.
RESULTS: IMR and LVEDP were both measured in 131 patients (mean age 59±10.7 years, 103 [78.6%] male, 48 [36.6%] 
with anterior myocardial infarction). The median IMR was 29 (interquartile range, 17–55), the median LVEDP was 17 mm Hg 
(interquartile range, 12–21), and the correlation between them was not statistically significant (r=0.15; P=0.087). Fifty-three 
patients (40%) had low IMR (≤32) and low LVEDP (≤18), 18 (14%) had low IMR and high LVEDP, 31 (24%) had high IMR and 
low LVEDP, while 29 (22%) had high IMR and high LVEDP. Infarct size (% LV mass), LV ejection fraction, final myocardial perfusion 
grade ≤1, TIMI (Thrombolysis In Myocardial Infarction) flow grade ≤2, and coronary flow reserve were associated with LVEDP/IMR 
group, as was hospitalization for heart failure (n=18 events; P=0.045) and major adverse cardiac events (n=21 events; P=0.051). 
LVEDP>18 and IMR>32 combined was associated with major adverse cardiac events, independent of age, estimated glomerular 
filtration rate, and infarct-related artery (odds ratio, 5.80 [95% CI, 1.60–21.22] P=0.008). The net reclassification improvement 
for detecting major adverse cardiac events was 50.6% (95% CI, 2.7–98.2; P=0.033) when LVEDP>18 was added to IMR>32.
CONCLUSIONS: IMR and LVEDP in combination have incremental value for risk stratification following primary percutaneous 
coronary intervention.
REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02257294.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
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Normal epicardial blood flow in the infarct-related artery is typically restored after primary percuta-neous coronary intervention (PCI).1 Microvascular 
injury following ST-segment–elevation myocardial infarc-
tion (STEMI) usually passes undetected in clinical prac-
tice and portends an increased risk of heart failure and 
death.2 While cardiovascular magnetic resonance (CMR) 
imaging reveals microvascular damage following STEMI, 
it is not feasible acutely, and hence is not useful for early 
risk stratification, to guide clinical decision-making and 
therapeutic management.
The index of microcirculatory resistance (IMR) mea-
sured at the end of primary PCI is a prognostically 
validated measure of microvascular reperfusion injury 
in acute STEMI.3,4 However, IMR is an imperfect prog-
nostic biomarker since about 70% of patients with an 
elevated IMR do not experience a major adverse cardiac 
event (MACE).5 Left ventricular end-diastolic pressure 
(LVEDP) is a clinically useful hemodynamic measure-
ment in STEMI. LVEDP>18 mm Hg increases the likeli-
hood of heart failure and death.6
IMR is mainly measured for research, and LVEDP is 
often omitted during routine primary PCI. However, both 
measurements are feasible and easily measured during 
primary PCI, therefore, there is potential for incorpora-
tion into routine clinical practice. The prognostic utility of 
IMR and LVEDP in combination is unknown. We aimed 
to assess the relative distribution of IMR and LVEDP in 
patients with acute STEMI, and whether the categoriza-
tion of patients using predefined, prognostic cutoffs of 
IMR and LVEDP, would associate with MACE (primary end 
point) and secondary end points (infarct size, LV ejection 
fraction, % ST-segment resolution, coronary flow reserve 
[CFR], TIMI [Thrombolysis In Myocardial Infarction] flow 
grade, and myocardial perfusion grade at the end of PCI). 
We further aimed to assess whether the prognostic asso-
ciations for a 4-level categorical classification would be 
greater than with either measurement alone.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
T-TIME (Trial of Low Dose Adjunctive Alteplase During 
Primary PCI) was a randomized, placebo-controlled, clinical trial 
of low-dose (10 and 20 mg) intracoronary alteplase in 440 
patients with STEMI.7 The trial protocol encouraged achieving 
TIMI flow grade ≥2, using balloon angioplasty/aspiration throm-
bectomy, before randomization. The 20 mL volume of study drug 
was then manually infused into the culprit artery, over 5 to 10 
minutes, proximal to the culprit lesion, using an intracoronary/
guiding catheter, prestent implantation. A physiology substudy 
was designated in 3 sites and found no associations between 
alteplase and LVEDP or IMR.8 Enrollment occurred from 2016 
to 2017 and was based on eligibility criteria, operator experi-
ence, and logistics at the point-of-care. The study was approved 
by the West of Scotland Research Ethics Committee (reference 
13-WS-0119) and all participants gave informed consent.
Eligibility
Patients were eligible to participate if they presented with persis-
tent ST-segment elevation or recent left bundle branch block, ≤6 
hours from symptom onset and with an occluded infarct-related 
artery, TIMI 1 flow (contrast passes beyond the obstruction but 
fails to opacify the entire coronary bed distally), or reduced coro-
nary flow (TIMI 2 flow, slow but complete filling), in the presence of 
TIMI thrombus grade ≥2. Key exclusion criteria (Data Supplement) 
included a functional coronary collateral supply (Rentrop grade 
≥2) to the infarct-related artery and cardiogenic shock.
Coronary Physiology
IMR and CFR were measured using a pressure- and temper-
ature-sensing guidewire (Abbott, Vascular, CA) at the end of 
Nonstandard Abbreviations and Acronyms
CFR coronary flow reserve
CMR cardiovascular magnetic resonance
IMR index of microcirculatory resistance
LV left ventricle
LVEDP left ventricular end-diastolic pressure
MACE major adverse cardiac events
PCI percutaneous coronary intervention
STEMI  ST-segment–elevation myocardial 
infarction
TIMI Thrombolysis In Myocardial Infarction
WHAT IS KNOWN
• The index of microcirculatory resistance of the 
infarct-related coronary artery and left ventricular 
end-diastolic pressure are acute, prognostic bio-
markers in patients undergoing primary percutane-
ous coronary intervention.
• Index of microcirculatory resistance and left ventric-
ular end-diastolic pressure are distinct and related 
hemodynamic measurements and their clinical sig-
nificance in combination is unknown.
WHAT THE STUDY ADDS
• A combinatory approach using index of microcir-
culatory resistance and left ventricular end-dia-
stolic pressure (low and high) discriminates major 
adverse cardiac events and infarct size more so 
than if either index is used alone.
• Risk stratification using index of microcirculatory 
resistance and left ventricular end-diastolic pres-
sure during primary percutaneous coronary inter-
vention has potential to guide patient selection for 
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PCI.3,4,9 Intracoronary nitroglycerin (200 µg) was administered 
into the infarct-related artery. A calibrated wire was equalized to 
guide catheter pressure, then advanced to the distal third of the 
infarct-related artery. Using standard thermodilution methods, 
the mean transit time of a hand injected 3 mL bolus of room 
temperature saline was measured in triplicate at rest and dur-
ing steady-state maximal hyperemia, induced by intravenous 
adenosine (140 µg/kg per minute).
The cardiologists were blinded to IMR, by obscuring the 
display of the RadiAnalyzer Xpress monitor. Physiology tech-
nicians recorded and quality-assured the thermodilution data. 
The physiology data were analyzed in a central laboratory by 
blinded researchers using Coroventis software (Coroventis 
Research AB, Uppsala, Sweden). IMR was defined as distal 
coronary pressure × mean transit time during steady-state 
hyperemia.3 A predefined threshold of 32 was used to dichoto-
mize IMR, because IMR>32 is prognostically significant3,4 and 
is also being used to select patients for inclusion in clinical tri-
als.10 CFR was quantified by dividing resting mean transit time 
by hyperemic mean transit time.9 A threshold of 2.0 was used 
to dichotomize CFR because based on published literature a 
CFR ≤2.0 is abnormal.9
Left Ventricular End-Diastolic Pressure
Measurement of LVEDP was recommended in the T-TIME 
protocol. Having positioned a right Judkins/pigtail catheter in 
the LV, the LVEDP was measured at the Z-point of change in 
the upstroke of the ventricular pressure that coincided with the 
R wave on the ECG.11 A prognostically significant predefined 
threshold of 18 mm Hg was used to dichotomize LVEDP.6
Angiographic and ECG Analyses
Angiographic and ECG end points were determined by blinded 
core laboratory analysis. The absolute percentage ST-segment 
resolution on ECGs obtained 60 minutes after reperfusion (ie, 
after initial restoration of flow in the infarct-related artery) com-
pared with prereperfusion was calculated.
CMR Imaging
CMR was performed at 1.5 Tesla, and the analysis was done 
by blinded researchers in a central laboratory. The presence 
of acute infarction was established based on abnormalities 
in cine wall motion, rest first-pass myocardial perfusion, and 
late gadolinium enhancement imaging, in 2 imaging planes. 
The myocardial mass of late gadolinium was quantified using 
a 5 SD semiautomated method and expressed as % of total 
LV mass. Myocardial salvage was calculated by subtraction 
of percent infarct size from percent area-at-risk (as reflected 
by the extent of edema), and the myocardial salvage index 
was calculated by dividing the myocardial salvage area by 
the initial area-at-risk. The CMR protocol has previously been 
described in detail.7
Health Outcomes
Information on serious adverse events during follow-up was 
obtained by site research staff. These events were indepen-
dently reviewed and adjudicated by a clinical events commit-
tee. Clinical events were assessed at 1 year. MACE, defined 
as cardiac death, nonfatal MI, or hospitalization for heart fail-
ure. Hospitalization for heart failure was defined as follows: (1) 
new or worsening signs/symptoms of heart failure requiring 
the initiation of, or increase in heart failure directed treatment 
(including intravenous therapy), or occurring in a patient already 
receiving maximal heart failure therapy or (2) confinement to 
bed predominantly due to heart failure symptoms or (3) pul-
monary edema sufficient to cause tachypnea and distress (not 
occurring in the context of an acute MI, worsening renal func-
tion [that is not wholly explained by worsening heart failure], 
or as the consequence of arrhythmia without worsening heart 
failure) or (4) cardiogenic shock.
Statistics
Continuous data were summarized using mean±SD, or median 
and interquartile ranges if skewed. Categorical variables were 
reported as frequency and percentages.
The study end points were compared in a 4-category com-
bination of high/low LVEDP and IMR, using the Kruskal-Wallis 
test (for skewed continuous end points), 1-way ANOVA (for 
normally distributed continuous end points), or the χ2 test (for 
categorical end points).
Analyses were also performed for associations between 
study end points and LVEDP>18 mm Hg or IMR>32 as binary 
predictors, using linear regression (continuous parameters), or 
logistic regression (categorical parameters). In regression mod-
els, logarithmic transformations were used where necessary to 
improve model residual distributions. The multivariable models 
were built by stepwise selection of baseline characteristics, 
with entry criteria set at the P<0.1 level. In addition to LVEDP 
and IMR, the following covariates were included in the multi-
variable model of infarct size at 3 months: body mass index, 
ischemic time, and infarct-related artery, and the following 
covariates were included in the multivariable model of MACE: 
age, estimated glomerular filtration rate, and infarct-related 
artery. Associations with health outcomes were evaluated using 
odds ratios derived from logistic regression. Furthermore, the 
incremental predictive ability of LVEDP>18, or IMR>32 for 
detecting health outcomes, was evaluated by the continuous 
net reclassification improvement.
All tests were 2-tailed, and a P value of <0.05 was consid-
ered statistically significant. Data were analyzed using R (ver-
sion 3.6.1, R Development Core Team, Auckland, New Zealand) 
and SPSS (version 25.0, SPSS, IBM, Armonk, NY).
RESULTS
Population
One hundred and thirty-one patients (mean age 59±10.7 
years, 103 [78.6%] male, 48 [36.6%] with anterior MI) 
had IMR and LVEDP measured at the end of primary 
PCI (Table 1; Figure 1). The primary mode of reperfu-
sion was balloon angioplasty or aspiration thrombectomy 
in 111 (84.7%) and 20 (15.3%) patients, respectively. 
The clinical and treatment characteristics of these par-
ticipants were generally similar to the trial population, 





 http://ahajournals.org by on February 24, 2021
Maznyczka et al Risk Stratification With LVEDP and IMR in Acute MI
Circ Cardiovasc Interv. 2021;14:e009529. DOI: 10.1161/CIRCINTERVENTIONS.120.009529 February 2021 168
IMR and LVEDP appeared to have skewed distribu-
tions (Figure I in the Data Supplement). The median IMR 
was 29 (interquartile range, 17–55), and the median 
LVEDP was 17 mm Hg (interquartile range, 12–21). The 
correlation between LVEDP and IMR was not statisti-
cally significant (Spearman ρ 0.15; P=0.087). The char-
acteristics that were associated with higher LVEDP, on 
multivariable linear regression, were higher body mass 
index (P<0.001), higher initial thrombus grade (P=0.003), 
and infarct-related artery (left anterior descending versus 
circumflex versus right coronary; P<0.001). The distribu-
tion of patients according to the predetermined cutoffs 
was LVEDP low (≤18 mm Hg) and IMR low (≤32), n=53 
(40%); LVEDP low and IMR high, n=31 (24%); LVEDP 












Age, y 59.0±10.7 56.8±9.2 56.9±10.7 60.3±11.8 63.2±11.1 0.070
Male 103 (78.6%) 46 (86.8%) 11 (61.1%) 24 (77.4%) 22 (75.9%) 0.156
Current smoker 64 (48.9%) 29 (22.1%) 8 (44.4%) 18 (58.1%) 9 (31.0%) 0.044
Diabetes* 15 (11.5%) 5 (9.45%) 2 (11.1%) 4 (12.9%) 4 (13.8%) 0.939
Hypertension 37 (28.2%) 13 (24.5%) 2 (11.1%) 10 (32.3%) 12 (41.4%) 0.127
Body mass index, kg/m2, median [IQR] 28.1 [24.8–30.4] 27.3 [24.5–29.5] 29.2 [24.9–31.6] 27.2 [24.41–29.4] 29.4 [26.7–32.7] 0.072
Previous MI 8 (6.15%) 2 (3.8%) 0 3 (9.7%) 3 (10.3%) 0.416
Estimated glomerular filtration rate,† 
mL/min per 1.73 m2
90.0 [76.7–102.8] 90.2 [84.0–101.0] 95.0 [78.0–102.0] 90.1 [78.0–111.0] 80.1 [68.0–103.0] 0.388
Ischemic time, h, median [IQR] 2.9 [2.1–3.9] 2.7 [2.0–3.8] 2.8 [1.9–4.3] 3.3 [2.8–4.3] 2.4 [2.0–3.5] 0.049
Infarct-related coronary artery
 Left anterior descending 49 (37.4%) 15 (28.3%) 9 (50.0%) 11(35.5%) 14 (48.3%) 0.441
 Right coronary 59 (45.0%) 28 (52.8%) 5 (27.8%) 15 (48.4%) 11 (37.9%)  
 Circumflex 23 (17.6%) 10 (18.9%) 4 (22.2%) 5 (16.1%) 4 (13.8%)  
Initial TIMI thrombus grade
 3 3 (2.3%) 2 (3.8%) 0 1 (3.2%) 0 0.348
 4 23 (17.6%) 8 (15.1%) 1 (5.6%) 9 (29.05) 5 (17.2%)  
 5 105 (80.2%) 43 (81.1%) 17 (94.4%) 21 (67.7%) 24 (82.8%)
Initial culprit artery TIMI flow grade
 0 103 (78.6%) 42 (79.2%) 16 (88.9%) 21 (67.7%) 24 (82.8%) 0.577
 1 13 (9.9%) 5 (9.4%) 0 5 (16.1%) 3 (10.3%)  
 2 15 (11.5%) 6 (11.3%) 2 (11.1%) 5 (16.1%) 2 (6.9%)  
 3 0 0 0 0 0  
PCI with stent implantation 131 (100.0%) 53 (100.0%) 18 (100.0%) 31 (100.0%) 29 (100.0%) …
Aspirin loading dose
 300 mg 129 (100.0%) 53 (100.0%) 16 (100.0%) 31 (100.0%) 29 (100.0%) …
 None 0 0 0 0 0  
Other antiplatelet medication
 Clopidogrel 78 (59.5%) 34 (64.2%) 10 (55.6%) 17 (54.8%) 17 (58.6%) 0.227
 Ticagrelor 51 (38.9%) 19 (35.8%) 6 (33.3%) 14 (45.2%) 12 (41.4%)  
 None 2 (1.5%) 0 2 (11.1%) 0 0  
Intracoronary alteplase during PCI
 10 mg 40 (30.5%) 15 (28.3%) 11 (61.1%) 3 (9.7%) 11 (37.9%) 0.015
 20 mg 44 (33.6%) 18 (34.0%) 3 (16.7%) 15 (48.4%) 8 (27.6%)  
 None 47 (35.9%) 20 (37.7%) 4 (22.2%) 13 (41.9%) 10 (34.5%)  
Data are mean±SD, or n (%) unless otherwise stated. P values are derived from the 1-way ANOVA, Kruskal-Wallis, or χ2 tests. IMR indicates index of microcirculatory 
resistance; IQR, interquartile range; LVEDP, left ventricular end-diastolic pressure; MI, myocardial infarction; PCI, percutaneous coronary intervention; and TIMI, Throm-
bolysis In Myocardial Infarction.
*Diabetes was defined as a history of diet-controlled or treated diabetes.
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high and IMR low, n=18 (14%); LVEDP high and IMR 
high, n=29 (22%).
CMR, Angiographic, and ECG End Points
The CMR findings at 2 to 7 days and 3 months for a 
4-category combination of IMR and LVEDP (low and 
high) are shown in Table 2. Also shown are angiographic 
end points CFR and % ST-segment resolution (Table 2).
A 4-category combination of IMR and LVEDP (low 
and high) had discriminative value for predicting infarct 
size, myocardial savage index, and LV ejection frac-
tion at 2 to 7 days and 3 months (Table 2). The CMR 
end points differed particularly when IMR and LVEDP 
were both low versus both high (Figures 2 and 3 and 
Table 2). When multivariable linear regression was 
performed, LVEDP>18 and IMR>32 combined was 
associated with 3-month infarct size, when compared 
with the low-risk group (LVEDP≤18 and IMR≤32 com-
bined; Table 3).
A 4-category combination of IMR and LVEDP (low 
and high) also predicted myocardial perfusion grade, 
TIMI flow grade, and CFR≤2 at the end of PCI (Table 2). 
Although a 4-category combination of IMR and LVEDP 
(low and high) was not associated with ST-segment res-
olution overall (Table 2), there was a significant differ-
ence in % ST-segment resolution when patients with low 
IMR and LVEDP were compared with patients with high 
IMR and LVEDP (coefficient: −19.0 [95% CI, −36.9 to 
−1.08]; P=0.038).
Figure 1. Flow of subjects through the study.
CMR indicates cardiovascular magnetic resonance; IMR, index of microcirculatory resistance; LVEDP, left ventricular end-diastolic pressure; 
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The results for the associations between CMR, angio-
graphic, or ECG end points with LVEDP>18 mm Hg and 
IMR>32 as binary predictors are reported in Tables II and 
III in the Data Supplement. The multivariable associates 
of infarct size at 3 months are described in Table 3.
Health Outcomes
A 4-category combination of IMR and LVEDP (low and 
high) had discriminative value for predicting MACE and 
hospitalization for heart failure at 1 year, particularly 
when IMR and LVEDP were both low versus both high 
(Table 2 and Figures 2 and 3). When multivariable logis-
tic regression was performed, LVEDP>18 and IMR>32 
combined was associated with MACE, when compared 
with the low-risk group (LVEDP≤18 and IMR≤32 com-
bined; Table 3).
The overall net reclassification improvement, reflect-
ing the incremental predictive accuracy for detecting 
MACE, was 50.6% (95% CI, 2.7–98.2; P=0.033) when 
LVEDP>18 was added to a baseline model incorporat-
ing IMR>32. When IMR>32 was added to LVEDP>18, 
the net reclassification improvement for detecting MACE 
was 49.7% (95% CI, 5.3–92.2; P=0.031).
When LVEDP>18 was added to a baseline model 
incorporating IMR>32, the overall net reclassification 
improvement for detecting heart failure hospitalization 
was 45.6% (95% CI, −5.7 to 97.9; P=0.081). When 
the baseline model incorporated LVEDP>18, the over-
all net reclassification improvement for detecting heart 
failure hospitalization was 61.3% (95% CI, 13.0–104.5; 
P=0.010) when IMR>32 was added.
The results for the associations between clinical out-
come and LVEDP>18 mm Hg and IMR>32 as binary 
predictors are reported in Tables II and III in the Data 
Supplement.
DISCUSSION
We described the associations and prognostic signifi-
cance of IMR and LVEDP combined as a 4-level cat-
egorical variable. We observed that MACE and the CMR, 
ECG and angiographic end points differed particularly 
when IMR and LVEDP were both low versus both high. 
We undertook multivariable analyses, which showed that 
LVEDP>18 and IMR>32 had incremental predictive util-
ity for detecting MACE. There were consistent, directional 
associations for infarct size and the IMR/LVEDP cat-
egory, providing a mechanism to explain the associations 
with MACE and LV ejection fraction. Our analysis identi-
fies IMR/LVEDP in combination as a novel biomarker 
for risk stratification during primary PCI. If future studies 
Table 2. CMR, ECG, and Angiographic End Points and Clinical Outcomes in 131 Participants in the T-TIME Trial Grouped Ac-












ECG, angiography, and coronary physiology
  % ST-segment resolution 60 minutes 
postreperfusion relative to baseline
46.1±41.4 54.3±40.0 53.3±30.5 38.1±51.6 35.3±34.6 0.133
 TIMI flow grade ≤2 after PCI 15 (11.5%) 1 (1.9%) 0 5 (16.1%) 9 (31.0%) <0.001
 MPG ≤1 after PCI 42 (32.1%) 11 (20.8%) 3 (16.7%) 12 (38.7%) 16 (55.2%) 0.005
 CFR at the end of PCI 1.4 [1.1–2.0] 1.8 [1.2–2.1] 1.8 [1.3–2.4] 1.2 [1.1–1.7] 1.2 [1.1–1.5] 0.001
CMR at day 2–7
 Infarct size (% LV) 23.1 [15.9–32.3] 19.8 [11.9–26.6] 25.4 [18.8–32.8] 25.4 [20.2–31.4] 31.2 [18.9–39.2] 0.016
 Myocardial salvage index 0.4 [0.2–0.6] 0.5 [0.2–0.7] 0.4 [0.2–0.6] 0.3 [0.2–0.4] 0.3 [0.2–0.5] 0.010
 LV ejection fraction, % 45.0 [40.2–49.7] 47.3 [42.1–51.1] 45.2 [42.4–47.2] 45.5 [39.3–50.8] 40.9 [32.5–46.4] 0.027
CMR at 3 mo
 Infarct size (% LV) 15.9 [7.5–24.6] 12.8 [2.8–18.7] 14.4 [7.5–20.7] 16.2 [11.6–25.3] 22.4 [14.8–28.3] 0.002
 Myocardial salvage index 0.6 [0.4–0.8] 0.7 [0.5–0.9] 0.7 [0.5–0.8] 0.4 [0.4–0.7] 0.4 [0.3–0.7] 0.001
 LV ejection fraction % 50.3 [45.7–54.6] 51.1 [47.5–55.1] 50.6 [49.1–55.2] 50.2 [46.4–54.0] 46.6 [38.5–50.9] 0.030
Health outcomes at 1 y
 MACE, n (%) 21 (16.0%) 4 (7.5%) 5 (16.1%) 3 (16.7%) 9 (31.0%) 0.051
 All-cause death, n (%) 2 (1.5%) 1 (1.9%) 0 (0.0%) 1 (5.6%) 0 (0.0%) 0.465
 Heart failure hospitalization, n (%) 18 (13.7%) 3 (5.7%) 5 (16.1%) 2 (11.1%) 8 (27.6%) 0.045
Values are median [IQR] unless otherwise stated. P values are derived from the 1-way ANOVA, Kruskal-Wallis, or χ2 tests. Missing data: CMR findings at 2–7 days—3 
subjects; infarct size or myocardial salvage index at 3 mo—8 subjects; LV ejection fraction at 3 mo—6 subjects; and ST-segment resolution—3 subjects. CFR indicates 
coronary flow reserve; CMR, cardiovascular magnetic resonance; IMR, index of microvascular resistance; LV, left ventricle; LVEDP, left ventricular end-diastolic pressure; 
MACE, major adverse cardiac events; MPG, myocardial perfusion grade; PCI, percutaneous coronary intervention; T-TIME, Trial of Low Dose Adjunctive Alteplase During 
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confirm this result, then IMR and LVEDP combined may 
represent a novel theragnostic biomarker for clinical and 
research purposes.
In our study,7 the distribution of IMR and LVEDP was 
similar to those of other populations.6,12,13 The associa-
tions between IMR/LVEDP category with the CMR and 
angiographic surrogates, and health outcomes were 
directionally consistent. The coherence of these results, 
derived from distinct methodologies, implies that a type 2 
statistical error is unlikely and the findings are plausible. 
Furthermore, fatal and nonfatal cardiovascular events 
were independently adjudicated by a clinical events 
committee blind to the LVEDP and IMR measurements, 
which strengthens the reliability of our findings.
Hospitalization for heart failure represented the 
majority of the MACE. Heart failure forms part of the 
natural history of acute MI and is a typical mode of death. 
Sudden cardiac death is directly related to infarct scar 
tissue and LV failure. The goal of effective reperfusion is 
to limit infarct size, preserve LV systolic function, and pre-
vent heart failure. Although heart failure post-MI may be 
considered a soft outcome, we suggest that it is a highly 
undesirable outcome post-MI, mechanistically linked to 
the efficacy of myocardial reperfusion2 and a key target 
for secondary prevention therapy.1
For the first time, we provide information on the prog-
nostic utility of LVEDP in combination with IMR. There-
fore, our study extends previous reports on associations 
between LVEDP and health outcomes, in patients with 
STEMI.6,11–13 In the HORIZONS-AMI trial (Harmonizing 
Outcomes With Revascularization and Stents in Acute 
Myocardial Infarction), LVEDP>18 mm Hg (median) during 
primary PCI was associated with increased rates of rein-
farction and death at 30 days and at 2 years (hazard ratio: 
Figure 2. Box and whisker plots for infarct size and left ventricular (LV) ejection fraction.
Differences in infarct size (A) and left ventricular (LV) ejection fraction (B) at 3 mo following primary percutaneous coronary intervention 
(PCI), between the 4-category groups of high/low left ventricular end-diastolic pressure (LVEDP; >18 and ≤18) and index of microcirculatory 
resistance (IMR; >32 and ≤32), and for LVEDP>18 and IMR>32 as independent binary factors. Boxes represent the median and interquartile 
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1.45 [95% CI, 1.14–1.85] P=0.002; n=2797).6 Therefore, 
an LVEDP threshold of 18 mm Hg was used in our article. 
A smaller study (n=1909) reported that an LVEDP>22 
mm Hg (median) was associated with increased heart fail-
ure rates at 90 days after primary PCI for.12 In a further 
study, higher LVEDP predicted mortality at 8 years follow-
ing primary PCI (hazard ratio: 1.18 [95% CI, 1.02–1.36] 
P=0.022, for 5 mm Hg incremental increase in LVEDP).13
It is mechanistically plausible that IMR and LVEDP 
used together may have greater prognostic utility than 
either parameter alone since these are distinct yet 
complimentary prognostic parameters. IMR is a spe-
cific measure of microvascular injury following STEMI. 
Microvascular injury has been implicated in worse health 
outcomes, due to impaired delivery of macrophages/
promoters needed for optimal infarct healing,14,15 and 
extravasation of blood when capillary integrity is com-
promised, leading to deposition of cytotoxic levels of 
iron in the myocardium, triggering inflammation, and 
fibrosis.16,17 When IMR is measured immediately fol-
lowing primary PCI, reversible edema may contribute to 
microvascular injury, which may partly explain why not all 
patients with elevated IMR have MACE.
In contrast, LVEDP measured during primary PCI 
reflects acute LV pump function, including the extent 
of ischemic injury, filling, contractility, and compliance. 
Because of the proximity of the vascular and myocardial 
compartments, intramyocardial vessels may be susceptible 
to changes in LV cavity pressure.18 An increased pressure 
in the LV cavity may result in transmitted external com-
pressive forces on the microcirculation, thereby increasing 
endocardial capillary pressure, which may, in turn, lead to 
decreased perfusion pressure, with subsequent impairment 
of microvascular perfusion in the territory of the infarct-
related artery.18,19 This concept is supported by correlations 
between LVEDP with zero-flow pressure.20 Other factors 
that may potentially affect LVEDP in acute STEMI include 
intravascular volume status21,22 and vasodilatory drugs, for 
example, nitrate, which may transiently reduce LVEDP.
Considering clinical translation, LVEDP and IMR are 
relatively straightforward to measure and well within the 
skill-sets of interventional cardiologists who perform 
Figure 3. Bar charts showing rates of major adverse cardiac events (MACE) and heart failure hospitalization.
Differences in major adverse cardiac events (MACE; A) and heart failure hospitalization (B) rates 1 y following primary percutaneous coronary 
intervention (PCI), between the 4-category groups of high/low left ventricular end-diastolic pressure (LVEDP; >18 and ≤18) and index of 
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primary PCI. LVEDP is a well-established hemodynamic 
biomarker, whereas clinicians are generally less familiar 
with IMR and potential barriers to measuring IMR include 
the cost of the guidewire and use of intravenous adenos-
ine. More research is needed to clarify whether LVEDP 
and IMR when used together might lead to improved 
patient outcomes, and if so, at what cost.
Limitations
The T-TIME population was selected for participation in a 
clinical trial, and LVEDP/IMR were not measured consecu-
tively in all patients. The low MACE rate limited power to 
detect statistically significant associations, therefore the 
findings should be interpreted as exploratory/hypothesis 
generating and not definitive. Moreover, continuous net 
reclassification improvement may overestimate the incre-
mental value of a biomarker,23 hence further research is 
needed to validate the findings. A further limitation is that the 
participants would not have withheld from caffeine because 
the procedures were performed in the emergency setting, 
which could have affected response to adenosine and thus 
maximal hyperemia could not be guaranteed in all patients.
Conclusions
IMR and LVEDP in combination have potential additive 
utility for immediate risk stratification during primary PCI 
for STEMI. Further research seems warranted.
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major adverse cardiac events; OR, odds ratio; and PCI, percutaneous coronary intervention.
*Left anterior descending versus circumflex versus right coronary artery.




 http://ahajournals.org by on February 24, 2021
Maznyczka et al Risk Stratification With LVEDP and IMR in Acute MI
Circ Cardiovasc Interv. 2021;14:e009529. DOI: 10.1161/CIRCINTERVENTIONS.120.009529 February 2021 174
drugs (alteplase 10 and 20 mg) and matched placebo. These organizations had 
no other involvement in the conduct of the study or in any aspect of the article.
Disclosures
Dr Berry is employed by the University of Glasgow which holds research and 
consultancy agreements with AstraZeneca, Abbott Vascular, Boehringer Ingel-
heim, GSK, HeartFlow, Neovasc, Opsens, and Novartis. Dr Oldroyd has received 
speaker fees and research support from Abbott Vascular and Boston Scientific. 
Dr Cotton reported research support and speaker fees from Abbott Vascular. 
Dr Ford has received speaker/consultancy fees from Abbott Vascular, Boehringer 
Ingelheim, Biotronik Bio-Excel, and Novartis. The other authors report no conflicts.
REFERENCES
 1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, 
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al; ESC Scientific 
Document Group. 2017 ESC Guidelines for the management of acute myo-
cardial infarction in patients presenting with ST-segment elevation: the task 
force for the management of acute myocardial infarction in patients pre-
senting with ST-segment elevation of the European Society of Cardiology 
(ESC). Eur Heart J. 2018;39:119–177. doi: 10.1093/eurheartj/ehx393
 2. Eitel I, de Waha S, Wöhrle J, Fuernau G, Lurz P, Pauschinger M, Desch S, 
Schuler G, Thiele H. Comprehensive prognosis assessment by CMR imag-
ing after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 
2014;64:1217–1226. doi: 10.1016/j.jacc.2014.06.1194
 3. Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, 
Loh JP, Oldroyd KG. Prognostic value of the index of microcirculatory resis-
tance measured after primary percutaneous coronary intervention. Circulation. 
2013;127:2436–2441. doi: 10.1161/CIRCULATIONAHA.112.000298
 4. Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, 
Schnittger I, Lee DP, Vagelos RH, Fitzgerald PJ, et al. Predictive value of 
the index of microcirculatory resistance in patients with ST-segment ele-
vation myocardial infarction. J Am Coll Cardiol. 2008;51:560–565. doi: 
10.1016/j.jacc.2007.08.062
 5. Maznyczka AM, Oldroyd KG, Greenwood JP, McCartney PJ, Cotton J, 
Lindsay M, McEntegart M, Rocchiccioli JP, Good R, Robertson K, et al. Com-
parative significance of invasive measures of microvascular injury in acute 
myocardial infarction. Circ Cardiovasc Interv. 2020;13:e008505. doi: 
10.1161/CIRCINTERVENTIONS.119.008505
 6. Planer D, Mehran R, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, 
Dudek D, Möckel M, Reyes SL, Stone GW. Prognostic utility of left ventricu-
lar end-diastolic pressure in patients with ST-segment elevation myocardial 
infarction undergoing primary percutaneous coronary intervention. Am J 
Cardiol. 2011;108:1068–1074. doi: 10.1016/j.amjcard.2011.06.007
 7. McCartney PJ, Eteiba H, Maznyczka AM, McEntegart M, Greenwood JP, 
Muir DF, Chowdhary S, Gershlick AH, Appleby C, Cotton JM, et al; T-TIME 
Group. Effect of low-dose intracoronary alteplase during primary percutane-
ous coronary intervention on microvascular obstruction in patients with acute 
myocardial infarction: a randomized clinical trial. JAMA. 2019;321:56–68. 
doi: 10.1001/jama.2018.19802
 8. Maznyczka AM, McCartney PJ, Oldroyd KG, Lindsay M, McEntegart M, 
Eteiba H, Rocchiccioli P, Good R, Shaukat A, Robertson K, et al. Effects of 
intracoronary alteplase on microvascular function in acute myocardial infarc-
tion. J Am Heart Assoc. 2020;9:e014066. doi: 10.1161/JAHA.119.014066
 9. Van Herck PL, Paelinck BP, Haine SE, Claeys MJ, Miljoen H, Bosmans JM, 
Parizel PM, Vrints CJ. Impaired coronary flow reserve after a recent myocardial 
infarction: correlation with infarct size and extent of microvascular obstruction. 
Int J Cardiol. 2013;167:351–356. doi: 10.1016/j.ijcard.2011.12.099
 10. Restoring Microcirculatory Perfusion in ST-Elevation Myocardial Infarction 
(STEMI): a randomised trial to evaluate the efficacy of low-dose intracoro-
nary tenecteplase in STEMI patients with high microvascular resistance 
post-percutaneous coronary intervention (PCI). ACTRN12618000778280. 
www.anzctr.org. Accessed: 12th August 2018.
 11. Leistner DM, Dietrich S, Erbay A, Steiner J, Abdelwahed Y, Siegrist PT, 
Schindler M, Skurk C, Haghikia A, Sinning D, et al. Association of left ven-
tricular end-diastolic pressure with mortality in patients undergoing per-
cutaneous coronary intervention for acute coronary syndromes. Catheter 
Cardiovasc Interv. 2020;96:E439–E446. doi: 10.1002/ccd.28839
 12. Bagai A, Armstrong PW, Stebbins A, Mahaffey KW, Hochman JS, 
Weaver WD, Patel MR, Granger CB, Lopes RD. Prognostic implications of 
left ventricular end-diastolic pressure during primary percutaneous coronary 
intervention for ST-segment elevation myocardial infarction: findings from 
the assessment of pexelizumab in acute myocardial infarction study. Am 
Heart J. 2013;166:913–919. doi: 10.1016/j.ahj.2013.08.006
 13. Ndrepepa G, Cassese S, Hashorva D, Kufner S, Xhepa E, Hasimi E, 
Fusaro M, Laugwitz KL, Schunkert H, Kastrati A. Relationship of left ven-
tricular end-diastolic pressure with extent of myocardial ischemia, myocar-
dial salvage and long-term outcome in patients with ST-segment elevation 
myocardial infarction. Catheter Cardiovasc Interv. 2019;93:901–909. doi: 
10.1002/ccd.28098
 14. Wu KC. CMR of microvascular obstruction and hemorrhage in myocardial 
infarction. J Cardiovasc Magn Reson. 2012;14:68. doi: 10.1186/1532- 
429X-14-68
 15. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarc-
tion: pathophysiology and therapy. Circulation. 2000;101:2981–2988. doi: 
10.1161/01.cir.101.25.2981
 16. Kali A, Kumar A, Cokic I, Tang RL, Tsaftaris SA, Friedrich MG, Dharmakumar 
R. Chronic manifestation of postreperfusion intramyocardial hemorrhage 
as regional iron deposition: a cardiovascular magnetic resonance study 
with ex vivo validation. Circ Cardiovasc Imaging. 2013;6:218–228. doi: 
10.1161/CIRCIMAGING.112.000133
 17. Carberry J, Carrick D, Haig C, Ahmed N, Mordi I, McEntegart M, Petrie MC, 
Eteiba H, Hood S, Watkins S, et al. Persistent iron within the infarct core 
after ST-segment elevation myocardial infarction: implications for left 
ventricular remodeling and health outcomes. JACC Cardiovasc Imaging. 
2018;11:1248–1256. doi: 10.1016/j.jcmg.2017.08.027
 18. Sezer M, van Royen N, Umman B, Bugra Z, Bulluck H, Hausenloy DJ, 
Umman S. Coronary Microvascular injury in reperfused acute myocar-
dial infarction: a view from an integrative perspective. J Am Heart Assoc. 
2018;7:e009949. doi: 10.1161/JAHA.118.009949
 19. Kirtane AJ, Bui A, Murphy SA, Karmpaliotis D, Kosmidou I, Boundy K, 
Rahman A, Pinto DS, Aroesty JM, Giugliano RP, et al; TIMI Study Group. 
Association of epicardial and tissue-level reperfusion with left ven-
tricular end-diastolic pressures in ST-elevation myocardial infarction. 
J Thromb Thrombolysis. 2004;17:177–184. doi: 10.1023/B:THRO. 
0000040486.10549.f6
 20. Van Herck PL, Carlier SG, Claeys MJ, Haine SE, Gorissen P, Miljoen H, 
Bosmans JM, Vrints CJ. Coronary microvascular dysfunction after myocar-
dial infarction: increased coronary zero flow pressure both in the infarcted 
and in the remote myocardium is mainly related to left ventricular filling 
pressure. Heart. 2007;93:1231–1237. doi: 10.1136/hrt.2006.100818
 21. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, 
Dua A, Short L, Kane K. Haemodynamic-guided fluid administration for the 
prevention of contrast-induced acute kidney injury: the POSEIDON ran-
domised controlled trial. Lancet. 2014;383:1814–1823. doi: 10.1016/ 
S0140-6736(14)60689-9
 22. Lima FV, Singh S, Parikh PB, Gruberg L. Left ventricular end diastolic pres-
sure and contrast-induced acute kidney injury in patients with acute coro-
nary syndrome undergoing percutaneous coronary intervention. Cardiovasc 
Revasc Med. 2018;19:16–20. doi: 10.1016/j.carrev.2018.06.002
 23. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclas-
sification indices for evaluating risk prediction instruments: a critical review. 




 http://ahajournals.org by on February 24, 2021
